Vergoeding 2017-2021 voor ATC-subgroep H01CB : Somatostatine en analogen
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| H01CB02 Octreotide (Sandostatine ®) | 23.379.500 | 23.427.100 | 22.726.900 | 21.123.500 | 15.067.200 |
| H01CB03 Lanreotide (Somatuline ®) | 18.775.100 | 20.823.000 | 23.342.800 | 25.068.200 | 22.373.200 |
| H01CB05 Pasireotide (Signifor ®) | 2.114.900 | 2.271.000 | 2.429.600 | 2.433.800 | 2.260.800 |
| Totaal | 44.269.500 | 46.521.100 | 48.499.300 | 48.625.500 | 39.701.200 |